AI Article Synopsis

  • Significant advancements in managing status epilepticus (SE) over the past decade have resulted from major trials, leading to a study that examines drug treatment evolution, outcomes, and differences between adults and children.
  • The analysis of medical records from 2012 to 2021 revealed that more children received prehospital treatment than adults, with midazolam use rising and older antiseizure medications declining in favor of newer options like levetiracetam.
  • Ultimately, midazolam has emerged as the preferred benzodiazepine for SE treatment, but overall mortality rates remained stable at 16.5% at discharge and 18.9% within 30 days during the study period.

Article Abstract

Background And Objectives: Over the last decade, significant advancements have been made in status epilepticus (SE) management, influenced by landmark trials such as ESETT and RAMPART. The objectives of this study were to explore the evolution of drug treatments for patients with SE, to investigate its association with outcomes and mortality, and to evaluate differences in treatment patterns between adults and children for a potential shift in medication trends due to the above mentioned trials.

Methods: The medical records of patients with SE treated at University Hospital Frankfurt between 2012 and 2021 were evaluated for medication trends and outcomes. Children and adults were analyzed separately and jointly.

Results: This study included 1151 SE episodes in 1021 patients (mean age = 53.3 ± 28.3 years; 52.5 % female [n = 533]). The overall percentage of patients with SE treated prehospital was stable over the last decade. More than half (53.6 %) of children were treated prehospital, compared with less than one-third (26.7 %) of adults. Prehospital midazolam use increased over time, while diazepam use decreased. Lorazepam was the most commonly used benzodiazepine in hospitals in 2012-2013, used in 40.8 % of all episodes. However, its use declined to 27.2 % in 2020-2021, while midazolam use increased to 44.0 %. While the use of older antiseizure medications (ASMs) such as phenobarbital (p = 0.02), phenytoin (p < 0.001), and valproate (p < 0.001) decreased, the use of newer ASMs such as levetiracetam and lacosamide significantly increased (p < 0.001). Propofol and continuous midazolam infusion remained the most used third-line therapy drugs. Overall mortality was 16.5 % at discharge and 18.9 % at 30 days. Mortality rates did not change between 2012 and 2021.

Conclusion: Midazolam has become the preferred benzodiazepine in pre- and in-hospital settings, both in children and adults. The same applies to the increased use of levetiracetam and lacosamide over time in children and adults, while phenobarbital, phenytoin, and valproate use decreased. Continuous midazolam infusion and propofol remain the most frequently used anesthetic drugs. Mortality and outcome remain stable despite changes in medication patterns.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667152PMC
http://dx.doi.org/10.1007/s40263-023-01049-wDOI Listing

Publication Analysis

Top Keywords

children adults
16
status epilepticus
8
medical records
8
university hospital
8
medication trends
8
patients treated
8
treated prehospital
8
midazolam increased
8
levetiracetam lacosamide
8
continuous midazolam
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!